Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes
Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.
'Not sustainable': The real impact of RVU cuts in electrophysiology
Despite a substantial increase in demand for electrophysiologists, payments for their services have remained stagnant.
Looking ahead to the future of FFR-CT
Current research suggests this technology is just getting started when it comes to transforming patient care.
Redo TAVR with balloon-expandable valves linked to positive outcomes, key improvements
Researchers tracked real-world data from more than 140 patients who originally received a transcatheter heart valve from Edwards Lifesciences, Medtronic or Boston Scientific.
Exploring the pros and cons of direct-to-patient drug programs
These programs may provide benefits in some cases. In others, however, there is a concern that they could actually lead to higher costs over time.

cardiologists evaluating the human heart to provide a treatment strategy

Redo TAVR: Supra-annular, intra-annular valves linked to comparable outcomes

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival.

HRS President, Mina Chung, MD, FHRS, staff cardiologist and Professor of Medicine in the Section of Pacing and Electrophysiology, Heart & Vascular Institute, Cleveland Clinic. Explains HRS accomplishments in the past year in terms of advocacy efforts and policy concerns impacting EP. #HRS2026 #EPeeps

Heart Rhythm 2026: Electrophysiologist Mina Chung discusses CPR, PFA and much more

Mina Chung, MD, who just concluded a one-year term as Heart Rhythm Society's president, spoke to Cardiovascular Business about successes from the past year as well as her goals for the future.

Heart Rhythm 2026 Program Chair Dhanunjaya "DJ" Lakkireddy, MD, MBA, FHRS, Executive Medical Director, Kansas City Heart Rhythm Institute, and professor of medicine at the University of Kansas Health System, offers an overview of key trends in electrophysiology (EP) technology.

PFA's dominance and other key electrophysiology trends on display at Heart Rhythm 2026

Heart Rhythm 2026 Program Chair DJ Lakkireddy, MD, spoke to Cardiovascular Business during the conference about several key EP trends.

The Society for Cardiovascular Angiography and Interventions (SCAI) is entering a new chapter as Dawn Abbott, MD, MSCAI, who assumeed the presidency this week with a focus on strengthening the future of interventional cardiology through workforce development, expanded training pathways and continued efforts to broaden inclusion in the specialty. #SCAI2026 #SCAI26

New SCAI President Dawn Abbott outlines workforce training and inclusion priorities

SCAI President Dawn Abbott, MD, MSCAI, aims to turn attention toward the long-term sustainability of the interventional cardiology field.

Cordis acquires MedAlliance, known for its drug-eluting balloon technology, in deal that could surpass $1B

Fewer stents, positive outcomes: Sirolimus-eluting balloons a safe alternative during PCI

Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.

GLP-1 receptor agonists (GLP-1-RAs) have become the wonder drug not only of weight loss, but also for improving cardiovascular health in a growing number of positive cardiovascular trials. The latest study of more than 13,000 patients presented at Heart Rhythm 2026 this week showed the GLP-1 reduce atrial fibrillation (AFib) and survival, even after accounting for the drug’s impact on weight loss.

Multiple GLP-1 drugs linked to lower AFib risk

The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.

heart data research doctor cardiologist AI

Two separate studies explored the value of treating heart patients with tirzepatide.

Emily Lau, MD, MPH, Director, Women's Heart Health Program, Brigham and Women's Hospital, presented new data at ACC 2026 showing only 8% of high-risk pregnant patients receive guideline-recommended low-dose aspirin to prevent preeclampsia.

Many high-risk pregnant patients still miss out on guideline-recommended care

The percentage of pregnant patients taking low-dose aspirin as recommended is slowly rising—but there is still a long way to go.

Cardiology Associations

Cardiologists and surgeons share early feedback after CMS proposed sweeping TAVR changes

'Not sustainable': The real impact of RVU cuts in electrophysiology

Looking ahead to the future of FFR-CT

Redo TAVR with balloon-expandable valves linked to positive outcomes, key improvements

Exploring the pros and cons of direct-to-patient drug programs